These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1355 related items for PubMed ID: 18357358

  • 21. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S, Graf N, Johansen P, Müllner G, Kündig TM, Senti G.
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [Abstract] [Full Text] [Related]

  • 22. [Bee and wasp venom allergy].
    Baumgartner A, Wokalek H, Schöpf E.
    Fortschr Med; 1989 Jul 20; 107(21):460-3. PubMed ID: 2670712
    [Abstract] [Full Text] [Related]

  • 23. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P.
    J Investig Allergol Clin Immunol; 2006 Jul 20; 16(2):79-85. PubMed ID: 16689180
    [Abstract] [Full Text] [Related]

  • 24. [Therapy control of specific hymenoptera venom allergy].
    Aust W, Wichmann G, Dietz A.
    Laryngorhinootologie; 2010 Dec 20; 89(12):725-8. PubMed ID: 21132618
    [Abstract] [Full Text] [Related]

  • 25. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization].
    Touraine F, Talayrach D, Florea O, Brianchon Ch, Preux PM, Bonnaud F.
    Eur Ann Allergy Clin Immunol; 2003 Nov 20; 35(9):335-9. PubMed ID: 14716961
    [Abstract] [Full Text] [Related]

  • 26. [Bee and wasp venom allergy. Clinical aspects, prevention and therapy].
    Ring J, Lonsdorf G, Schury W, Burg G.
    MMW Munch Med Wochenschr; 1982 Jun 18; 124(24):587-90. PubMed ID: 6810134
    [No Abstract] [Full Text] [Related]

  • 27. [Risk factors for allergy to hymenoptera stings].
    Leveau P.
    Allerg Immunol (Paris); 1993 Jun 18; 25(6):220, 224-6. PubMed ID: 8357470
    [Abstract] [Full Text] [Related]

  • 28. [Desensitization of allergy to hymenoptera venoms].
    Przybilla B, Ruëff F.
    Wien Med Wochenschr; 1999 Jun 18; 149(14-15):421-8. PubMed ID: 10584286
    [Abstract] [Full Text] [Related]

  • 29. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A, Boerzsoenyi J, Babilas P, Landthaler M, Szeimies RM.
    J Dtsch Dermatol Ges; 2008 Apr 18; 6(4):292-7. PubMed ID: 18042250
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [A modified ultra-rush-protocol of allergen immunotherapy in children and adolescents with insect venom allergy].
    Steiss JO, Hüls G, Gortner L, Lindemann H.
    Klin Padiatr; 2004 Apr 18; 216(2):79-82. PubMed ID: 15106079
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Mastocytosis and insect venom allergy.
    Bonadonna P, Zanotti R, Müller U.
    Curr Opin Allergy Clin Immunol; 2010 Aug 18; 10(4):347-53. PubMed ID: 20485157
    [Abstract] [Full Text] [Related]

  • 36. Hymenoptera sting anaphylaxis: detection and clinical significance of individual bee and wasp venoms specific IgE and IgG4 antibodies.
    Ameno S, Ameno K, Fuke C, Shinohara T, Kiriu T, Kinoshita H, Ijiri I.
    Nihon Hoigaku Zasshi; 1993 Jun 18; 47(3):207-12. PubMed ID: 8345683
    [Abstract] [Full Text] [Related]

  • 37. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy.
    Ruëff F, Bilò MB, Jutel M, Mosbech H, Müller U, Przybilla B, Interest group on Hymenoptera venom allergy of the European Academy of Allergology and Clinical Immunology.
    J Allergy Clin Immunol; 2009 Jan 18; 123(1):272-3; author reply 273. PubMed ID: 19130944
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
    Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, Campodonico P, Milani M.
    Ann Allergy Asthma Immunol; 2009 Jul 18; 103(1):57-61. PubMed ID: 19663128
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 68.